Stock Events

Stock Events

Vyome 

0
70
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24NovExpected
Q1 2026
Q2 2026
Next
-0.18
-0.15
-0.12
-0.09
Expected EPS
-0.1811523
Actual EPS
N/A

Financials

-2,455.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
347,899.45Revenue
-8.54MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow H1O.MU. It's not an investment recommendation.
Microsoft
3
MSFT
Amazon
3
AMZN
NVIDIA
3
NVDA
Main Street Capital
3
MAIN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap116.77B
Medtronic offers products in the obesity and metabolic health sector, directly competing with ReShape's weight loss solutions.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its subsidiary Ethicon, provides bariatric surgery products that compete with ReShape's offerings.
Boston Scientific
BSX
Mkt Cap67.88B
Boston Scientific Corporation competes in the market for minimally invasive medical devices, including those for weight loss and metabolic health.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories offers various medical devices and nutritional products that can be seen as alternatives to weight loss surgeries.
Penumbra
PEN
Mkt Cap12.67B
Penumbra, Inc. focuses on innovative medical devices, potentially entering into or competing in the obesity management space.
Sensus Healthcare
SRTS
Mkt Cap57.95M
Sensus Healthcare, Inc. specializes in non-invasive treatments and could expand into non-surgical weight loss solutions.
Intuitive Surgical
ISRG
Mkt Cap131.63B
Intuitive Surgical, Inc. provides robotic-assisted surgical systems that can be used in bariatric surgery, competing with ReShape's solutions.
Edwards Lifesciences
EW
Mkt Cap52B
Edwards Lifesciences Corporation is involved in patient-focused medical innovations, which could include obesity management solutions.
Stryker
SYK
Mkt Cap126.84B
Stryker Corporation, a medical technology company, has the potential to offer products that compete in the obesity and metabolic health sector.
Zimmer Biomet
ZBH
Mkt Cap19.25B
Zimmer Biomet Holdings, Inc. focuses on musculoskeletal healthcare but has the potential to venture into obesity management solutions.

About

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Show more...
CEO
Venkateswarlu Nelabhotla
Employees
18
Country
United States
ISIN
US92943X1046
WKN
000A3D3E9

Listings

XNAS
US
HIND
MU
DE
H1O.MU
BOATS
BOATS
HIND.BOATS

0 Comments

Share your thoughts

FAQ

What is Vyome stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Vyome stocks are traded under the ticker H1O.MU.
Is Vyome stock price growing?▼
H1O.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Vyome has showed a -39.68% decrease.
When is the next Vyome earnings date?▼
Vyome is going to release the next earnings report on November 24, 2026.
What were Vyome earnings last quarter?▼
H1O.MU earnings for the last quarter are -0.09 EUR per share, whereas the estimation was -0.16 EUR resulting in a +47.37% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Vyome revenue for the last year?▼
Vyome revenue for the last year amounts to 347,899.45 EUR.
What is Vyome net income for the last year?▼
H1O.MU net income for the last year is -8.54M EUR.
How many employees does Vyome have?▼
As of September 02, 2026, the company has 18 employees.
In which sector is Vyome located?▼
Vyome operates in the Health & Wellness sector.
When did Vyome complete a stock split?▼
The last stock split for Vyome was on August 15, 2025 with a ratio of 1:4.
Where is Vyome headquartered?▼
Vyome is headquartered in SAN CLEMENTE, United States.